Compare ZJYL & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZJYL | MOLN |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | China | Switzerland |
| Employees | 273 | N/A |
| Industry | Industrial Specialties | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.9M | 170.5M |
| IPO Year | 2020 | 2021 |
| Metric | ZJYL | MOLN |
|---|---|---|
| Price | $1.99 | $4.21 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.38 |
| AVG Volume (30 Days) | ★ 38.9K | 1.5K |
| Earning Date | 08-20-2025 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $374.07 |
| P/E Ratio | $18.40 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $3.53 |
| 52 Week High | $4.50 | $5.36 |
| Indicator | ZJYL | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 38.64 | 50.27 |
| Support Level | $1.94 | $4.13 |
| Resistance Level | $2.59 | $4.21 |
| Average True Range (ATR) | 0.18 | 0.15 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 18.25 | 42.05 |
Jin Medical International Ltd, along with its subsidiaries, mainly offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other assistive living aid products for use by people with disabilities or impaired mobility. The group's product offering includes wheelchairs and wheelchair components, oxygen concentrators, bathing machines, respiratory and walking aids, oxygen chambers, beauty instruments, and nano products, among others. Wheelchairs are currently its key revenue-generating product. The products are sold to dealers in Japan and China, and to some extent to dealers located in the United States, Canada, Australia, Korea, Israel, Singapore, and other regions. Geographically, the group generates maximum revenue from Japan.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.